Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Selected City: Dhaka

Grocery
Pharmacy
Cookups
  • Offers
  • Egg Club
  • Daily Deals
  • Favourites
  • Common Conditions 
  • Sexual Wellness
  • Birth Control Contraceptives
  • Vitamins & Supplements 
  • Medical Devices
  • Medical Accessories
  • Personal Care 
  • Health & Wellness 
  • Baby Care 
  • Premium Care
  • Food Aid
  • Recipes
Help
File a complaint

    Salost Tablet 5mg

    7 tablets
    ৳56
    0
    in bag

    Product Information

    SALOST

    Salost DR 35mg®

    Risedronate Sodium

    Presentation

    Salost 5mg tablet: Yellow, capsule shaped, film coated tablet; each tablet contains Risedronate Sodium hemi-pentahydrate USP

    equivalent to Risedronate Sodium 5mg.

    Salost DR 35mg tablet: White, oval shaped, delayed release tablet; each tablet contains Risedronate Sodium hemi-pentahydrate USP

    equivalent to Risedronate Sodium 35mg.

    Salost 150mg tablet: Blue, oval shaped, film coated tablet; each tablet contains Risedronate Sodium hemi-pentahydrate USP

    equivalent to Risedronate Sodium 150mg.

    Indications

    Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal

    osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of

    osteoporosis. To maintain or increase bone mass in postmenopausal women undergoing long-term (more than 3 months), systemic

    corticosteroid treatment at doses 7.5mg/day prednisone or equivalent. Treatment of osteoporosis in men at high risk of fractures.

    Dosage and administration

    Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures and treatment of established postmenopausal

    osteoporosis, to reduce the risk of hip fractures: The recommended dose is Risedronate Sodium 5mg (one Salost 5mg tablet) once

    daily or Risedronate Sodium 35mg (one Salost DR 35mg tablet) once weekly on the same day each week or Risedronate Sodium 150mg

    (one Salost 150mg tablet) once monthly.

    Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis: The recommended dose is Risedronate Sodium

    5mg (one Salost 5mg tablet) once daily.

    To maintain or increase bone mass in postmenopausal women undergoing long-term (more than 3 months), systemic corticosteroid

    treatment at doses 7.5mg/day prednisone or equivalent: The recommended dose is Risedronate Sodium 5mg (one Salost 5mg tablet) once

    daily.

    Treatment of osteoporosis in men at high risk of fractures: The recommended dose is Risedronate Sodium 35mg (one Salost DR 35mg

    tablet) once weekly. The tablet should be taken on the same day each week.

    Method of administration: The absorption of Risedronate Sodium film coated tablets are affected by food, thus to ensure adequate

    absorption patients should take Salost (Risedronate Sodium film coated) 5mg & 150mg tablets at least 30 minutes before the first

    food, other medicinal product or drink (other than plain water) of the day.

    Salost (Risedronate Sodium film coated) 5mg & 150mg tablet: In the particular instances that before breakfast dosing is not

    practical, Salost (Risedronate Sodium film coated) 5mg tablet can be taken between meals or in the evening at the same time

    everyday, with strict adherence to the following instructions, to ensure Risedronate Sodium film coated tablet is taken on an

    empty stomach- Between meals: Risedronate Sodium film coated tablet should be taken at least 2 hours before and at least 2 hours

    after any food, medicinal product or drink (other than plain water). In the evening: Risedronate Sodium film coated tablet should

    be taken at least 2 hours after the last food, medicinal product or drink (other than plain water) of the day.

    Salost DR (Risedronate Sodium delayed release) 35mg tablet: Should be taken in the morning, with breakfast, (this may include high

    fat foods, coffee, tea, milk, orange juice, etc. Salost DR (Risedronate Sodium delayed release) 35mg tablets should not be chewed,

    cut, or crushed. Care should be taken not to break the outer coating which is designed to remain intact until the tablet reaches

    the small intestine where the tablet coating dissolves and release the active ingredient.

    If a dose is missed: Salost (Risedronate Sodium film coated) 5mg tablet: If an occasional dose is missed, Salost (Risedronate

    Sodium film coated) 5mg tablet can be taken before breakfast, between meals, or in the evening according to the instructions

    above.

    Salost DR (Risedronate Sodium delayed release) 35mg tablet: Patients should be instructed that if a dose is missed, just take one

    Salost DR (Risedronate Sodium delayed release) 35mg tablet on the morning after remember. Patients should then return to taking

    one tablet once a week on the day the tablet is normally taken. Two tablets should not be taken on the same day.

    Salost (Risedronate Sodium film coated) 150mg tablet: Patient should be instructed that if a dose is missed and the next month’s

    schedule dose is more than 7 days away, then should take the missed tablet in the morning after the day it is remembered. Patients

    should then return to taking one tablet once a month normally taken.

    Salost (Risedronate Sodium film coated) 5mg, Salost DR (Risedronate Sodium delayed release) 35mg & Salost (Risedronate Sodium film

    coated) 150mg tablets must be swallowed whole and not sucked or chewed. To aid delivery of the tablet to the stomach Salost

    (Risedronate Sodium film coated) 5mg, Salost DR (Risedronate Sodium delayed release) 35mg & Salost (Risedronate Sodium film

    coated) 150mg tablets are to be taken while in an upright position with a glass of plain water (120ml or more). Patients should

    not lie down for 30 minutes after taking the tablet. Supplemental calcium and vitamin D should be considered if the dietary intake

    is inadequate.

    Elderly: No dosage adjustment is necessary since bioavailability, distribution and elimination were similar in elderly (60 years

    of age or older) compared to younger subjects. This has also been shown in the very elderly, 75 years old and above postmenopausal

    population.

    Renal impairment: No dosage adjustment is required for those patients with mild to moderate renal impairment. The use of

    Risedronate Sodium is contra-indicated in patients with severe renal impairment (Creatinine clearance lower than 30ml/min).

    Contra-indications, warnings, etc

    Contra-indications: Risedronate Sodium tablet is contra-indicated in patients

    with known hypersensitivity to Risedronate Sodium and in patients with hypocalcaemia, severe renal impairment (creatinine

    clearance lower than 30ml/min), during pregnancy and lactation.

    Precautions: Foods, drinks (other than plain water) and medicinal products containing polyvalent cations (such as calcium,

    magnesium, iron and aluminium) interfere with the absorption of bisphosphonates and should not be taken at the same time as

    Risedronate Sodium. In order to achieve the intended efficacy, strict adherence to dosing recommendations is necessary. Efficacy

    of bisphosphonates in the treatment of osteoporosis is related to the presence of low bone mineral density and/or prevalent

    fracture. High age or clinical risk factors for fracture alone are not sufficient reasons to initiate treatment of osteoporosis

    with a bisphosphonate. The evidence to support efficacy of bisphosphonates including Risedronate in the very elderly (>80 years)

    is limited. Bisphosphonates have been associated with oesophagitis, gastritis, oesophageal ulcerations and gastroduodenal

    ulcerations. Thus, caution should be used in patients who have a history of oesophageal disorders which delay oesophageal transit

    or emptying (e.g. stricture or achalasia) or in patients who are unable to stay in the upright position for at least 30 minutes

    after taking the tablet or if Risedronate is given to patients with active or recent oesophageal or upper gastrointestinal

    problems. Prescribers should emphasize to patients the importance of paying attention to the dosing instructions and be alert to

    any signs and symptoms of possible oesophageal reaction. The patients should be instructed to seek timely medical attention if

    they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain or new/worsened

    heartburn. Hypocalcaemia should be treated before starting Risedronate Sodium therapy. Other disturbances of bone and mineral

    metabolism (i.e. parathyroid dysfunction, hypovitaminosis D) should be treated at the time of starting Risedronate Sodium therapy.

    Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been

    reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphophonates. Many

    of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in

    patients with osteoporosis receiving oral bisphosphonates. A dental examination with appropriate preventive dentistry should be

    considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy,

    radiotherapy, corticosteroids, poor oral hygiene). While on treatment, these patients should avoid invasive dental procedures if

    possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the

    condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of

    bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgment of the treating physician should guide

    the management plan of each patient based on individual benefit /risk assessment.

    Use in pregnancy and lactation: There are no adequate data from the use of Risedronate Sodium in pregnant women. Studies in

    animals have shown reproductive toxicity. The potential risk for humans is unknown. Studies in animal indicate that a small amount

    of Risedronate Sodium pass into breast milk. Risedronate Sodium must not be used during pregnancy or by breast-feeding women.

    Pediatric use: Safety and efficacy of Risedronate Sodium tablet have not been established in children and adolescents.

    Side effects: Common: headache, constipation, dyspepsia, nausea, abdominal pain, diarrhoea, musculoskeletal pain. Uncommon:

    gastritis, oesophagitis, dysphasia, duodenitis, oesophageal ulcer. Rare: glossitis, oesophageal stricture.

    Drug interactions: No formal interaction studies have been performed, however no clinically relevant interactions with other

    medicinal products were found during clinical trials. Among regular acetyl salicylic acid or NSAID users (3 or more days per week)

    the incidence of upper gastrointestinal adverse events in Risedronate Sodium tablet treated patients was similar to that in

    control patients. If considered appropriate Risedronate Sodium may be used concomitantly with oestrogen supplementation (for women

    only). Concomitant ingestion of medications containing polyvalent cations (e.g. calcium, magnesium, iron and aluminium) will

    interfere with the absorption of Risedronate Sodium. Risedronate Sodium is not systemically metabolized, does not induce

    cytochrome P450 enzymes, and has low protein binding.

    Overdose: No specific information is available on the treatment of overdose with Risedronate Sodium. Decreases in serum calcium

    following substantial overdose may be expected. Signs and symptoms of hypocalcaemia may also occur in some of these patients. Milk

    or antacids containing magnesium, calcium or aluminium should be given to bind Risedronate and reduce absorption of Risedronate

    Sodium. In cases of substantial overdose, gastric lavage may be considered to remove unabsorbed Risedronate Sodium.

    Pharmaceutical precautions

    Store in a cool and dry place protected from light.

    Packaging quantities

    Salost 5mg tablet: Carton containing 28 tablets in alu-alu blister.

    Salost DR 35mg tablet: Carton containing 4 tablets in alu-alu blister.

    Salost 150mg tablet: Carton containing 1 tablet in alu-alu blister.

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]